Illumina, Inc.

• ILMN Stock Price 24h change: -1.70%. From 146.99 USD to 144.56 USD.
The decline was largely driven by a general market pullback following a multi-day rally and cautious investor sentiment after the J.P. Morgan Healthcare Conference, despite the company's recent AI and data-centric product announcements.• Key Technical Indicators: RSI(14) is 49.10 (Neutral); MACD is -0.50 (Sell); 200-Day SMA is 136.03 (Buy).
Technically, the stock is in a "neutral-to-bullish" long-term phase; while the price remains above major long-term moving averages (50-day and 200-day), short-term momentum has cooled as the RSI nears the midpoint, suggesting a consolidation period before any further breakout attempt toward the 52-week high of $153.• Illumina introduced the "Billion Cell Atlas" on January 13, a massive AI-driven genetic dataset in partnership with AstraZeneca, Merck, and Eli Lilly to accelerate drug discovery.
• CEO Jacob Thaysen declared 2026 a "revolutionary year" for precision health at the J.P. Morgan Healthcare Conference, highlighting the new BioInsight unit focused on multiomics and AI.
• Illumina announced it will report its fourth quarter and full year 2025 financial results on February 5, 2026.• 10x Genomics reported preliminary Q4 2025 revenue of $166 million, showing 11% sequential growth but a sharp 39% annual decline in instrument sales, reflecting ongoing capital expenditure caution in biotech.
• The broader Life Sciences sector is shifting focus toward "execution over promise" in 2026, with heavy investments in cell and gene therapies (CGTs) which reached $15.2 billion globally in the past year.

• ILMN Stock Price 24h change: -2.22%. From 148.51 USD to 145.30 USD. The decline followed a period of strong gains, as investors potentially locked in profits despite positive announcements regarding the "Billion Cell Atlas" and updated FY2025 earnings guidance that exceeded consensus estimates.
• From a technical perspective, ILMN maintains a "bullish momentum with short-term consolidation": shares are trading above the 200-day SMA ($136.03) and 50-day SMA ($129.40), signaling a long-term uptrend. While the 14-day RSI is neutral at 49.10, the MACD (-0.50) suggests a short-term bearish crossover, indicating the stock is currently digesting recent vertical moves near its 52-week high.
• Illumina unveiled the "Billion Cell Atlas" on January 15, 2026, the world's largest genome-wide genetic perturbation dataset developed with partners like AstraZeneca and Merck to accelerate AI-driven drug discovery.
• On January 13, 2026, Illumina raised its FY2025 earnings guidance to $4.76–$4.79 per share, surpassing the Wall Street consensus of $4.51, and announced the appointment of Dr. Eric Green as Chief Medical Officer.
• Illumina launched "Illumina Connected Multiomics" on January 12, a cloud-based software platform designed to integrate proteomic and genomic data, which analysts expect to drive precision health breakthroughs.
• Bank of America highlighted the Life Sciences Tools sector for growth in 2026, noting that easing uncertainty in pharmaceutical end-markets and the integration of AI in diagnostics are key tailwinds for industry leaders.
• The U.S. medtech and life sciences sector entered 2026 with a focus on "productivity and AI-enabled decision making," as procedure volumes normalized and companies shifted toward high-margin recurring services and data-driven biology.